




European
AIDS Treatment
Group



Международная коалиция по готовности к лечению
Восточная Европа и Центральная Азия

ACCESS, SERVICES, KNOWLEDGE (ASK):

ЛЕЧЕНИЕ ВИЧ И СОПУТСТВУЮЩИХ
ИНФЕКЦИЙ (ГЕПАТИТ С И ТУБЕРКУЛЕЗ)



“Access, Services, Knowledge (ASK): Treatment of HIV and coinfections (hepatitis C and tuberculosis)”

This initiative has been independently developed by the European AIDS Treatment Group (EATG), which is partially sponsored by BMS, Sidaction and Positive Action. EATG acknowledges that BMS, Sidaction and Positive Action have had no control or input into the content or the structure of the initiative.

With the financial support of



Bristol-Myers Squibb



Training Minutes

Training participants: representatives of non-governmental organizations, social workers and healthcare workers from Ukraine, Russia, and Azerbaijan.

Trainers: Denis Godlevskiy (St. Petersburg), Stephan Dressler (Berlin), Svilen Konov (London).

This initiative has been independently developed by the European AIDS Treatment Group (EATG), which is partially sponsored by BMS, Sidaction and Positive Action. EATG acknowledges that BMS, Sidaction and Positive Action have had no control or input into the content or the structure of the initiative.

With the financial support of



Bristol-Myers Squibb



Training topics

1. HIV/HCV/TB Epidemiology in Eastern Europe and Central Asia	4
2. TB Diagnostics	4
3. TB Treatment	4
4. Compulsory Treatment, Quarantine, Isolation, In-Patient and Out-Patient TB Care	4
5. Hepatitis C at a Glance	5
6. HCV Diagnostics	5
7. Hepatitis C Treatment	5
8. Pipeline of HCV Drugs	5
9. HIV Cure	6

This initiative has been independently developed by the European AIDS Treatment Group (EATG), which is partially sponsored by BMS, Sidaction and Positive Action. EATG acknowledges that BMS, Sidaction and Positive Action have had no control or input into the content or the structure of the initiative.

With the financial support of



Bristol-Myers Squibb



HIV/HCV/TB EPIDEMIOLOGY IN EASTERN EUROPE AND CENTRAL ASIA

Key terms: epidemiology, prevalence, incidence, mortality, cumulative number, cure rate.

HIV statistics in the world and in Eastern Europe and Central Asia with a focus on participating countries (Azerbaijan, Russia, Ukraine). Specifics of the epidemic in EECA.

TB:

- Statistics in the world and in EECA
- Countries with the highest disease burden, WHO country TB profiles (<http://www.who.int/tb/country/data/profiles/ru>)
- Drug-resistant TB, HIV/TB coinfection statistics.

Hepatitis C (HCV):

- Statistics in the world and in EECA
- HCV programmes in EECA
- Key affected populations

TB DIAGNOSTICS

Testing:

- Who should be tested on a priority bases (vulnerable groups, routine and preventive screening of people belonging to certain professions and/or groups, people living with HIV (PLHIV).
- What is important to know in the context of TB testing; testing approaches; testing patients with HIV.
- Clinical symptoms of TB.
- Types of testing (immunology, microbiology, molecular diagnostics, fluorography and X-ray of affected organs and systems, computer tomography, rapid testing) – advantages and disadvantages.
- Testing of patients with known TB (drug sensitivity and drug resistance).
- What is new in the field of TB testing.

TB TREATMENT

- Drugs for treating TB
- Treatment approaches: treatment standards; Treatment of HIV/TB coinfection, MDR- and XDR-TB (multi-drug resistant TB and extensively drug-resistant TB).

COMPULSORY TREATMENT, QUARANTINE, ISOLATION, IN-PATIENT AND OUT-PATIENT TB CARE

- DOTS (directly observed treatment short course): principles and approaches for treating TB

This initiative has been independently developed by the European AIDS Treatment Group (EATG), which is partially sponsored by BMS, Sidaction and Positive Action. EATG acknowledges that BMS, Sidaction and Positive Action have had no control or input into the content or the structure of the initiative.

With the financial support of



Bristol-Myers Squibb



- TB treatment in specialized facilities
- When should a TB-patient be isolated?
- Compulsory treatment: examples from the countries of the region

TB Prevention

- Risk groups; risk factors for getting infected with TB.
- Risk management (public healthcare, infectious control, individual medical surveillance, environment control, administrative issues).
- 3-I approach

HEPATITIS C AT A GLANCE

- Types of Hepatitis C
- Hepatitis B, C, D (prevalence in the region, transmission routes, testing for hepatitis B, C, D; consequences of hepatitis C; manifestation and symptoms).
- Treating monoinfected patients and patients coinfecting with HIV.
- Prevention and control.

HCV DIAGNOSTICS

- Basic terms (antigen, antibody, classes of antibodies);
- Types of diagnostics (PCR, genotyping, non-invasive diagnostics).
- HCV testing interpretation (anti-HCV IgM, anti-HCV core IgG, anti-HCV NS IgG, RNA HCV).
- EASL 2014 testing recommendations (EASL, 2014)
- Rapid testing

HEPATITIS C TREATMENT

- Terminology (using the example of treating HCV with pegylated interferons and ribavirin): rapid virologic response, early virologic response, delayed virologic response, null response, partial response, sustained virologic response, breakthrough, relapse.
- HCV treatment (treatment standards, treating different HCV genotypes, treatment efficacy, treating HCV with pegylated interferons, protease inhibitors, direct-acting antiviral drugs; treating patients with HIV/HCV co-infection); when to start treatment).
- New Chronic HCV Treatment Recommendations (EASL, 2014; EACS HIV/HCV Treatment Recommendations, 2014).

PIPELINE OF HCV DRUGS

- Overview of direct-acting antiviral drugs (Harvoni, Viekirax, daclatasvir).
- Drugs in the pipeline.

This initiative has been independently developed by the European AIDS Treatment Group (EATG), which is partially sponsored by BMS, Sidaction and Positive Action. EATG acknowledges that BMS, Sidaction and Positive Action have had no control or input into the content or the structure of the initiative.

With the financial support of



Bristol-Myers Squibb



HIV CURE

- Issues with curing HIV
- Approaches to curing HIV (early treatment, strengthening ART, combining ART with immunotherapy, activating and terminating HIV, gene therapy, combined approaches).
- Failures in the history of HIV cure (Berlin patient, Mississippi baby).
- HIV cure trials: regulatory and ethical issues.

This initiative has been independently developed by the European AIDS Treatment Group (EATG), which is partially sponsored by BMS, Sidaction and Positive Action. EATG acknowledges that BMS, Sidaction and Positive Action have had no control or input into the content or the structure of the initiative.

With the financial support of



Bristol-Myers Squibb



**POSITIVE
ACTION**